| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net cash provided by financing activities | 309,612 | 12,846 |
| Effect of exchange rate changes on cash | 94 | 121 |
| Decrease in cash | -11,759 | -104,638 |
| Cash and cash equivalents at beginning of period | 309,776 | - |
| Cash and cash equivalents at end of period | 298,017 | - |
CRISPR Therapeutics AG (CRSP)
CRISPR Therapeutics AG (CRSP)